Verification of the interaction between peptide T and CD4 using surface plasmon resonance

Tracie E. Ramsdale; Peter R. Andrews; Edouard C. Nice

doi:10.1016/0014-5793(93)80657-G

Verification of the interaction between peptide T and CD4 using surface plasmon resonance

Tracie E. Ramsdale, Peter R. Andrews, Edouard C. Nice

Research output: Contribution to journal › Article › Research › peer-review

21 Citations (Scopus)

Abstract

Peptide T is currently in phase II clinical trials for the treatment of AIDS-associated dementia. Its putative mode of action is inhibition of binding of the HIV envelope protein (gp120) to its cellular receptor (CD4), thus preventing viral infectivity and gp120-induced neuronal toxicity. However, a number of reports have appeared in the literature which have failed to observe any inhibitory activity of Peptide T on CD4-gp120 binding, thus casting doubt on this hypothesis. This study uses a novel biosensor technique to demonstrate that Peptide T does bind to CD4 and that this binding can be specifically inhibited by an anti-CD4 monoclonal antibody. A detailed analysis of the kinetics of the interaction is presented.

Original language	English
Pages (from-to)	217-222
Number of pages	6
Journal	FEBS Letters
Volume	333
Issue number	3
DOIs	https://doi.org/10.1016/0014-5793(93)80657-G
Publication status	Published - 1 Nov 1993
Externally published	Yes

Keywords

AIDS-associated dementia
Biosensor
Kinetics
Peptide T
Surface plasmon resonance

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/0014-5793(93)80657-G

Cite this

@article{b0b4de4a5ecd4e3296ea5c4ce148e9e7,

title = "Verification of the interaction between peptide T and CD4 using surface plasmon resonance",

abstract = "Peptide T is currently in phase II clinical trials for the treatment of AIDS-associated dementia. Its putative mode of action is inhibition of binding of the HIV envelope protein (gp120) to its cellular receptor (CD4), thus preventing viral infectivity and gp120-induced neuronal toxicity. However, a number of reports have appeared in the literature which have failed to observe any inhibitory activity of Peptide T on CD4-gp120 binding, thus casting doubt on this hypothesis. This study uses a novel biosensor technique to demonstrate that Peptide T does bind to CD4 and that this binding can be specifically inhibited by an anti-CD4 monoclonal antibody. A detailed analysis of the kinetics of the interaction is presented.",

keywords = "AIDS-associated dementia, Biosensor, Kinetics, Peptide T, Surface plasmon resonance",

author = "Ramsdale, {Tracie E.} and Andrews, {Peter R.} and Nice, {Edouard C.}",

year = "1993",

month = nov,

day = "1",

doi = "10.1016/0014-5793(93)80657-G",

language = "English",

volume = "333",

pages = "217--222",

journal = "FEBS Letters",

issn = "0014-5793",

publisher = "John Wiley & Sons",

number = "3",

}

TY - JOUR

T1 - Verification of the interaction between peptide T and CD4 using surface plasmon resonance

AU - Ramsdale, Tracie E.

AU - Andrews, Peter R.

AU - Nice, Edouard C.

PY - 1993/11/1

Y1 - 1993/11/1

N2 - Peptide T is currently in phase II clinical trials for the treatment of AIDS-associated dementia. Its putative mode of action is inhibition of binding of the HIV envelope protein (gp120) to its cellular receptor (CD4), thus preventing viral infectivity and gp120-induced neuronal toxicity. However, a number of reports have appeared in the literature which have failed to observe any inhibitory activity of Peptide T on CD4-gp120 binding, thus casting doubt on this hypothesis. This study uses a novel biosensor technique to demonstrate that Peptide T does bind to CD4 and that this binding can be specifically inhibited by an anti-CD4 monoclonal antibody. A detailed analysis of the kinetics of the interaction is presented.

AB - Peptide T is currently in phase II clinical trials for the treatment of AIDS-associated dementia. Its putative mode of action is inhibition of binding of the HIV envelope protein (gp120) to its cellular receptor (CD4), thus preventing viral infectivity and gp120-induced neuronal toxicity. However, a number of reports have appeared in the literature which have failed to observe any inhibitory activity of Peptide T on CD4-gp120 binding, thus casting doubt on this hypothesis. This study uses a novel biosensor technique to demonstrate that Peptide T does bind to CD4 and that this binding can be specifically inhibited by an anti-CD4 monoclonal antibody. A detailed analysis of the kinetics of the interaction is presented.

KW - AIDS-associated dementia

KW - Biosensor

KW - Kinetics

KW - Peptide T

KW - Surface plasmon resonance

UR - http://www.scopus.com/inward/record.url?scp=0027424056&partnerID=8YFLogxK

U2 - 10.1016/0014-5793(93)80657-G

DO - 10.1016/0014-5793(93)80657-G

M3 - Article

C2 - 8224182

AN - SCOPUS:0027424056

SN - 0014-5793

VL - 333

SP - 217

EP - 222

JO - FEBS Letters

JF - FEBS Letters

IS - 3

ER -

Verification of the interaction between peptide T and CD4 using surface plasmon resonance

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Cite this